

Technical Data Sheet

Product Anti-Hu CD25 Purified

Cat. Number/Size 11-299-C025 0.025 mg

11-299-C100 0.1 mg

For Research Use Only.

Not for use in diagnostic or therapeutic procedures.

Antigen CD25

Clone MEM-140
Format Purified
Reactivity Human

Application FC (QC tested), IP

Application details Immunoprecipitation: Excellent for immunoisolation of CD25<sup>+</sup> cells.

Flow cytometry: Recommended dilution: 1 µg/ml.

Isotype Mouse IgM

Specificity The antibody MEM-140 reacts with an extracellular epitope of CD25 (Interleukin-2 receptor alpha chain), a

55 kDa type I transmembrane glycoprotein expressed on activated B and T lymphocytes, activated monocytes/macrophages and on CD4<sup>+</sup> T lymphocytes (T regulatory cells); it is lost on resting B and T

lymphocytes.

Other names IL-2R  $\alpha$  chain, IL-2-RA, IL2-RA, p55, TAC antigen, IDDM10, TCGFR

Workshop HLDA VI: WS Code C C-54

Immunogen PHA-activated peripheral blood leucocytes

Entrez Gene ID 3559
Gene name IL2RA

NCBI Full Gene Name interleukin 2 receptor subunit alpha

UniProt ID P01589

Concentration 1 mg/ml

Preparation Purified by sequential steps of physicochemical fractionation (differential precipitation and solid-phase

chromatography methods).

Formulation Tris buffered saline (TBS), pH 8.0, 15 mM sodium azide

Storage and handling Store at 2-8°C. Do not freeze.

Images and References www.exbio.cz

The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

Revision date: 2025-01-02